P reeclampsia, a multisystem disorder unique to pregnancy, is a serious and potentially life-threatening condition complicating 2% to 5% of all pregnancies. 1 The current management of patients suspected of preeclampsia is often increased monitoring and hospital admission because of the risk of liver, lung, and kidney damages, eclampsia, prematurity, intrauterine growth restriction, and maternal and fetal demise, which is also accompanied by the immense cost to society.
outcome is still limited. 13, 15, 16 Recent studies that included sFlt-1, PlGF, or the sFlt-1/PlGF ratio on top of a model with traditional predictors [17] [18] [19] consistently restricted their outcome to the diagnosis of preeclampsia while from a clinical perspective, a more relevant question is how to identify patients at risk for adverse maternal and perinatal outcomes.
In the present study, we assessed the incremental value of sFlt-1, PlGF, and their ratio for the prediction of maternal and fetal/neonatal complications and pregnancy prolongation in a high-complication risk cohort of women with suspected or with confirmed preeclampsia. We explicitly chose to analyze the continuous values of the biomarkers rather than dichotomized values in previous studies to use as much information as possible.
Methods

Study Design
Women with singleton pregnancies from varied ethnic background with suspicion/confirmed preeclampsia were recruited into this prospective multicenter cohort study from December 2013 through April 2016 at 3 Dutch hospitals (Erasmus MC and Maasstad Hospital in Rotterdam, Reinier de Graaf Hospital in Delft). Identical study protocol and data collection forms were used at each center. All subjects provided written informed consent to participate in the study, which was approved by the local research ethics committee (MEC-2013-202 ).
Study Population
The inclusion criteria were singleton pregnant women who were either suspected of preeclampsia or with a confirmed diagnosis of preeclampsia from gestational age (GA) of ≥20 weeks admitted to the obstetric departments of participating hospitals. Patients were included if the treating physician deemed an evaluation of preeclampsia necessary. Indication for evaluation included: elevated blood pressure or proteinuria or symptoms associated with preeclampsia, such as right upper quadrant abdominal pain or headache with visual disturbances. Women with multiple pregnancy, chromosomal/fetal anomalies, and GA <20 weeks were excluded.
Diagnosis
Preeclampsia was defined according to the International Society for the Study of Hypertension as de novo hypertension (systolic blood pressure of ≥140 or diastolic blood pressure [DBP] of ≥90 mm Hg) and proteinuria (protein-to-creatinine ratio ≥30 mg/mmol or ≥300 mg/24 hours or 2+ dipstick) at or after 20 weeks of pregnancy. 20 The preeclampsia group was further divided into preeclampsia, superimposed preeclampsia, and HELLP syndrome. Superimposed preeclampsia was diagnosed in women with chronic hypertension with new onset of proteinuria or a sudden increase of blood pressure or appearance of thrombocytopenia and increased liver enzymes or a sudden increase of proteinuria in patients with a preexisting proteinuria. The group with only suspicion of preeclampsia, but without gestational hypertension, was defined as no hypertensive disease of pregnancy.
Outcome Measures
Maternal complications were defined as eclampsia, development of (superimposed) preeclampsia or the HELLP syndrome after inclusion in to the study, pulmonary edema, subcapsular liver hematoma, cerebral hemorrhage/edema or infarction, postpartum hemorrhage (blood loss ≥1000 mL after delivery), and acute renal failure (absolute increase in the serum creatinine concentration of ≥0.3 mg/dL [26.4 μmol/L] from baseline; ≥50% increase in serum creatinine; or oliguria with <0.5 mL/kg per hour for a period of 6 hours). All patients diagnosed with superimposed preeclampsia, preeclampsia, or HELLP at initial inclusion (n=213) were excluded from the calculation of maternal complications.
Fetal/neonatal complications were defined as fetal death, neonatal (birth) weight <10th percentile according to Perinatal Registration, The Netherlands; development of sepsis; admittance to the neonatal intensive care unit; artificial ventilation and its duration; bronchopulmonary dysplasia, defined as chronic lung disease developing in preterm neonates treated with oxygen and positive-pressure ventilation, with radiographic signs of inflammation and scarring, in need of artificial ventilation 4 weeks post-partum and at 36 weeks postmenstrual age; respiratory distress syndrome; necrotizing enterocolitis; intraventricular hemorrhage; periventricular leukomalacia and posthemorrhagic ventricular dilatation. All patients (n=620) were used for the calculation of fetal/neonatal complications.
Days until delivery was defined as days from study inclusion and blood sampling until delivery. Because pregnancies complicated with preeclampsia beyond 37 weeks' gestation (ie, term) are delivered to initiate resolution of preeclampsia, the additive value of the biomarkers was only calculated for women included to the study <37 weeks' gestation (n=422). The predictive and additive value of the biomarkers was also calculated for women included before 34 weeks of gestation at blood draw (n=254) in view of reports that with advancing gestation sFlt-1 and PlGF values in preeclamptic and healthy pregnancies tend to converge. [21] [22] [23] Clinical findings, physical examination, laboratory test results, maternal and fetal/neonatal complications (diagnosed by the treating physicians), and background data were obtained from patient's electronic medical records and ascertained by 3 independent researchers.
Serum Samples
For the measurement of sFlt-1 and PlGF, serum was prepared from venous whole blood, and assays were performed at the clinical laboratory of the Erasmus MC using an automated biochemistry analyzer (Cobas 6000, e module; Roche Diagnostics, Mannheim, Germany). Samples were stored at −80°C until analysis. Blood was drawn at inclusion, but values of sFlt-1 and PlGF were measured post-partum to prevent any influence of this information on decision making of the treating physicians.
Statistical Analysis
Logistic regression analysis was used to study the association between the dichotomous outcomes (maternal and fetal/neonatal complications) and the novel biomarkers, traditional predictors, and traditional laboratory variables. Linear regression analysis was used for the continuous outcome number of days until delivery. The associations of the biomarkers with the outcomes were studied with restricted cubic spline functions and shown in graphs.
Traditional predictors concerned GA, parity, proteinuria (proteinto-creatinine ratio, 24-hour urine collection, or dipstick test), and DBP (model 1). Systolic blood pressure was not considered because of its high correlation with DBP. Indeed, a model with systolic blood pressure rather than DBP gave a similar fit. Traditional laboratory variables included serum concentrations of alanine aminotransaminase, creatinine, uric acid, lactate dehydrogenase, and platelets, and these were added to model 1 (model 2). sFlt-1, PlGF, or the sFtl-1/ PlGF ratio were either alone or in combination added to model 1 or 2 to assess their incremental value. Furthermore, the incremental value of dichotomous variants of the sFtl-1/PlGF ratio was assessed based on previous suggested cutoff values, 13 ≤38 or >85. Models were compared using concordance (c)-statistic for the dichotomous outcomes and R 2 for the continuous outcome. We used SPSS Statistics 21 (IBM Corporation) and R Software for the statistical analysis.
Results
From January 2014 to June 2016, 620 pregnant women (age 18-48 years) were included (Table 1) . GA was <34 weeks in 254 (41%) and between 34 and 37 weeks in 168 (27%) women. At time of inclusion, 288 (46%) women were suspected of preeclampsia but had no hypertensive disease of pregnancy, 118 (19%) were diagnosed with gestational hypertension, and 213 (34%) were diagnosed with (superimposed) preeclampsia/HELLP (Table 1 ). In total, 136 maternal complications occurred in 123 (20%) women, and 245 (40%) of the pregnancies had fetal/neonatal complications (n=506, ie, often >1 complication per patient; Table 2 ).
Maternal Complications
Higher values of sFlt-1 and sFlt-1/PlGF ratio were linearly associated with a higher risk of maternal complications ( Figure) . Higher values of PlGF were associated with lower maternal risk, with low risks from 300 pg/mL onwards. All 3 markers had clear discriminative ability with C-indices between 0.73 and 0.78 in univariable analysis (Table 3) . When sFlt-1, PlGF, or sFlt-1/PlGF ratio were added to a model with traditional predictors and laboratory variables (model 2), the C-index increased from 0.73 for a model without biomarkers to 0.83, 0.79, and 0.82 respectively. This indicates the incremental value of the biomarkers. If 2 of the 3 angiogenic parameters (sFlt-1, PlGF, and their ratio) were added together to model 2, the C-index increased to 0.83 in all combinations (ie, to a value identical to that achieved by adding sFlt-1 alone). The incremental value of the dichotomized values for the ratio cutoffs ≤38 or >85 was lower than for the continuous values (C-indices of 0.81 and 0.76, respectively).
After exclusion of postpartum hemorrhage as a maternal complication, all 3 markers still had clear discriminative ability with C-indices between 0.73 and 0.77 in univariable analysis. When the markers were added to model 2, the C-index increased from 0.78 to 0.86 or 0.87. This again illustrates the incremental value of the biomarkers. The highest C-index (0.88) was observed for model 2 plus 2 of the 3 angiogenic parameters (sFlt-1, PlGF, and their ratio). The incremental value of the dichotomized values for the ratio cutoffs ≤38 or >85 was lower than for the continuous value (C-indices of 0.85 and 0.83, respectively).
Fetal/Neonatal Complications
Higher values of sFlt-1 and sFlt-1/PlGF ratio were linearly associated with higher risk of fetal/neonatal complications ( Figure) . Higher values of PlGF were associated with lower fetal/neonatal risk. Univariate analysis revealed that both PlGF and sFlt-1/PlGF ratio had clear discriminative ability with C-indices of 0.78 and 0.75, respectively (Table 4) . Addition of sFlt-1, PlGF, or sFlt-1/PlGF ratio to a model with traditional predictors and laboratory variables (model 2) increased the C-index from 0.78 for a model without biomarkers to 0.85, 0.86, and 0.86, respectively. This indicates the incremental value of the biomarkers. If 2 of the 3 angiogenic parameters (sFlt-1, PlGF, and their ratio) were added together to model 2, the C-index increased to 0.88 in all combinations (ie, to a value higher than that achieved by any parameter alone). The incremental value of the dichotomized values for the ratio cutoffs ≤38 or >85 was lower than for the continuous value (C-indices in both cases 0.80).
Days Until Delivery
Higher values of sFlt-1 and sFlt-1/PlGF ratio were linearly associated with higher risk of early delivery (Figure) . Higher values of PlGF were associated with lower risk of early delivery. All 3 markers only modestly predicted days until delivery with R 2 between 0.22 and 0.33 in univariable analysis (Table 5 ). When sFlt-1, PlGF, or sFlt-1/PlGF ratio were added to a model with traditional predictors and laboratory variables (model 2), the R 2 increased from 0.53 for a model without biomarkers to 0.60, 0.72, and 0.71, respectively. This indicates the incremental value of the biomarkers. If 2 of the 3 angiogenic parameters (sFlt-1, PlGF, and their ratio) were added together to model 2, the R 2 increased to 0.72 in all Values are median (interquartile range). HELLP indicates hemolysis, elevated liver enzymes, and low platelets; PlGF, placental growth factor; and sFlt-1, soluble Fms-like tyrosine kinase 1.
combinations (ie, to a value identical to that achieved by adding PlGF alone). The incremental value of the dichotomized values for the ratio cutoffs ≤38 or >85 increased the R 2 to 0.65 and 0.64, respectively.
As expected, if calculations were restricted to women with a GA of <34 weeks, the predictive value of the biomarkers was substantially greater both in univariable analysis and when added to model 2. The largest increase, to 0.79, was achieved by adding PlGF. When 2 of the 3 angiogenic parameters (sFlt-1, PlGF, and their ratio) were added together to model 2, the R 2 increased to 0.79 in all combinations (ie, again to a value identical to that achieved by adding PlGF alone). Values are n (percentage) or *median (interquartile range); †other intracerebral complications include stroke, cysts, developmental anomalies, meningitis, and vasculopathy. HELLP indicates hemolysis, elevated liver enzymes, and low platelets; PlGF, placental growth factor; and sFlt-1, soluble Fms-like tyrosine kinase 1.
The incremental value of the dichotomized values for the ratio cutoffs ≤38 or >85 increased R 2 to 0.72 and 0.71, respectively.
Associations of sFlt-1, PlGF, and sFlt-1/PlGF Ratio With Traditional Laboratory Measurements and Blood Pressure
Traditional laboratory measurements as well as DBP correlated only weakly with the individual angiogenic biomarkers and the sFlt-1/PlGF ratio, the strongest association being present between serum uric acid and the sFlt-1/PlGF ratio (r=0.40; Table S1 in the online-only Data Supplement). This is in line with the additive value of incorporating the various angiogenic markers in model 2.
Discussion
This study, performed in a high-risk cohort of 620 women with suspected/confirmed preeclampsia, shows clear incremental value of sFlt-1, PlGF, or their ratio over clinical and traditional laboratory variables that are known to be associated with adverse pregnancy outcomes and to predict maternal and fetal/ neonatal complications, as well as pregnancy prolongation. Our findings suggest that sFlt-1, PlGF, and the sFlt-1/PlGF ratio in univariable analysis predict maternal and fetal/neonatal complications to at least the same degree as, if not better than, the combination of all clinical and traditional laboratory variables. In univariable analysis, the biomarkers were relatively weak predictors of time until delivery, but when added individually to a model with clinical and traditional laboratory variables, the prediction of pregnancy prolongation improved considerably. In line with previous studies, 7,21-23 the predictive value of the biomarkers was even higher when limiting our analysis to women with a GA <34 weeks. This was also the case for maternal and fetal/neonatal outcomes (data not shown).
The traditional laboratory parameters did not show incremental value on top of the traditional clinical variables (GA, parity, DBP, and proteinuria) for fetal/neonatal complications, suggesting that the information of the traditional laboratory parameters exclusively concerns maternal health. In the past, various cutoff values of the sFlt-1/PlGF ratio have been proposed to predict the (short-term) absence or presence of preeclampsia or pregnancy-related complications. 12, 16, 23, 24 In our cohort, we have, therefore, compared the additional predictive value of the thresholds ≤38 and >85 of the ratio with the predictive value of the continuous values of the individual biomarkers and their ratio, either alone or in combination. For all outcome parameters, the predictive accuracy of these thresholds was lower than when the biomarkers were used as continuous variables. Our data thus illustrate that the absolute values of sFlt-1 and PlGF in combination with standard clinical and laboratory assessment have superior predictive ability compared with dichotomous versions of the biomarkers. Although we acknowledge the easier applicability of thresholds, our data suggest that loss of predictive performance may be a potential disadvantage of this approach. In part, this can be overcome by using different cutoff values for different GAs as suggested in several previous studies, 12, 15 but this in turn blurs the convenience of a single cutoff point. Furthermore, when we applied the proposed sFlt-1/PlGF ratio threshold of ≤38 to predict the short-term absence of preeclampsia, 13 we still observed patients who developed preeclampsia-related complications (false negatives; Table 2 ).
Most studies applying models including angiogenic markers focused on the diagnosis of preeclampsia as end point instead of pregnancy outcome. 13, 17, [25] [26] [27] In a small cohort of 51 women with singleton pregnancies and early onset preeclampsia, a high sFlt-1/PlGF ratio was predictive for perinatal but not maternal complications. 28 Two large studies performed in women with singleton pregnancies showed that PlGF and sFlt-1 measured at, respectively, 30 to 34 weeks' and 35 to 37 weeks' gestation were poor or no predictors of stillbirth or adverse events in labor or after birth, including admission to the neonatal intensive care unit, which occurred in, respectively, 5.9% and 6.3% of newborns. 25, 26 In the present study, 41.8% of newborns were admitted to the neonatal intensive care unit, reflecting the inclusion of a high-risk group in our study. Our study, therefore, is the first to allow robust conclusions on the predictive value of the angiogenic biomarkers with regard to days until delivery and maternal and fetal/ neonatal adverse events.
Several limitations of our study must be acknowledged. First, the biomarkers were not measured at fixed time points, related in part to variation in outpatient visits. Nonetheless, this reflects clinical reality. Second, we did not perform repeated angiogenic marker measurements during pregnancy. Although repeated measurements might improve the prediction of pregnancy outcomes, an important question is how frequently one has to repeat the measurement of these proteins, especially when women are suspected of preeclampsia early in pregnancy. Here, the costs of determining these markers multiple times should also be considered. Traditional model 1 consists of gestational age, parity, diastolic blood pressure, and proteinuria; Traditional model 2 consists of model 1 plus serum concentrations of creatinine, uric acid, alanine transaminase, lactate dehydrogenase, and platelets; Multivariable includes the traditional predictors with either sFlt-1, PlGF, sFtl-1/PlGF ratio, sFtl-1/PlGF ratio ≤38, or sFtl-1/PlGF ratio >85. CI indicates confidence interval; GA, gestational age; PlGF, placental growth factor; and sFlt-1, soluble Fms-like tyrosine kinase 1.
